Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (11424)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Jul 15, 2020 (publication date) through Nov 28, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Diabetes
ISSN
1948-9358
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Grubić Rotkvić P, Cigrovski Berković M, Bulj N, Rotkvić L, Ćelap I. Sodium-glucose cotransporter 2 inhibitors’ mechanisms of action in heart failure. World J Diabetes 2020; 11(7): 269-279 [PMID: 32843930 DOI: 10.4239/wjd.v11.i7.269] |
|---|---|
| URL: | https://www.wjgnet.com/1948-9358/full/v11/i7/269.htm |
| Number | Citing Articles |
| 1 |
Naresh Kanumilli, Martin Miszon, Oliver Schnell, Per-Henrik Groop. The role of finerenone in the management of CKD in T2D –Practical considerations for primary care. Primary Care Diabetes 2024; 18(6): 565 doi: 10.1016/j.pcd.2024.09.001
|
| 2 |
Magdy Abdelhamid, Hossam Kandil, Mahmoud Hassanin, Sameh Shaheen, Mohamed Sobhy, Adel ElEtreby, Hosam Hasan‐Ali, Hala Mahfouz, Gamila Nasr, Islam Shawky, Sameh Emil, Mohamed ElSetiha, Mohamed Hasssan, Yasser Sadek, Mohamed Abdelghany Karim, Ayman Asham, Mohamed Ghaleb, Ahmad Samir, Khaled Shokry. Egyptian expert opinion for the use of sodium‐glucose cotransporter‐2 inhibitors in patients with heart failure with reduced ejection fraction. ESC Heart Failure 2022; 9(2): 800 doi: 10.1002/ehf2.13811
|
| 3 |
Petra Grubić Rotkvić, Ivana Ćelap, Valerija Bralić Lang, Juraj Jug, Andrea Snagić, Ivana Huljev Šipoš, Maja Cigrovski Berković. Impact of SGLT2 inhibitors on the mechanisms of myocardial dysfunction in type 2 diabetes: A prospective non-randomized observational study in patients with type 2 diabetes mellitus without overt heart disease. Journal of Diabetes and its Complications 2023; 37(8): 108541 doi: 10.1016/j.jdiacomp.2023.108541
|
| 4 |
Fares E. M. Ali, Emad H. M. Hassanein, Omnia A. M. Abd El‐Ghafar, Eman K. Rashwan, Fayez M. Saleh, Ahmed M. Atwa. Exploring the cardioprotective effects of canagliflozin against cisplatin‐induced cardiotoxicity: Role of iNOS/NF‐κB, Nrf2, and Bax/cytochrome C/Bcl‐2 signals. Journal of Biochemical and Molecular Toxicology 2023; 37(4) doi: 10.1002/jbt.23309
|
| 5 |
Christopher Cunningham, Ahmad Jabri, Laith Alhuneafat, Ashish Aneja. A Comprehensive Guide to Sodium Glucose Cotransport Inhibitors. Current Problems in Cardiology 2023; 48(10): 101817 doi: 10.1016/j.cpcardiol.2023.101817
|
| 6 |
Si Gao, Xue-ping Liu, Ting-ting Li, Li Chen, Yi-ping Feng, Yu-kun Wang, Yan-jun Yin, Peter J. Little, Xiao-qian Wu, Suo-wen Xu, Xu-dong Jiang. Animal models of heart failure with preserved ejection fraction (HFpEF): from metabolic pathobiology to drug discovery. Acta Pharmacologica Sinica 2024; 45(1): 23 doi: 10.1038/s41401-023-01152-0
|
| 7 |
Li Wang, Xiaoning Guo. Efficacy and safety of SGLT2 inhibitors in patients with heart failure. Medicine 2022; 101(3): e28636 doi: 10.1097/MD.0000000000028636
|
| 8 |
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki, Christos Mantzoros. Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism 2022; 137: 155332 doi: 10.1016/j.metabol.2022.155332
|
| 9 |
Petra Grubić Rotkvić, Zrinka Planinić, Ana-Marija Liberati Pršo, Jozica Šikić, Edvard Galić, Luka Rotkvić. The Mystery of Diabetic Cardiomyopathy: From Early Concepts and Underlying Mechanisms to Novel Therapeutic Possibilities. International Journal of Molecular Sciences 2021; 22(11): 5973 doi: 10.3390/ijms22115973
|
| 10 |
Wei Yan, Song Wen, Ligang Zhou. Effect of Intestinal Flora on Hyperuricemia-Induced Chronic Kidney Injury in Type 2 Diabetic Patients and the Therapeutic Mechanism of New Anti-Diabetic Prescription Medications. Diabetes, Metabolic Syndrome and Obesity 2023; : 3029 doi: 10.2147/DMSO.S429068
|
| 11 |
Andrea Giaccari, Roberto Pontremoli, Pasquale Perrone Filardi. SGLT-2 inhibitors for treatment of heart failure in patients with and without type 2 diabetes: A practical approach for routine clinical practice. International Journal of Cardiology 2022; 351: 66 doi: 10.1016/j.ijcard.2021.12.050
|
| 12 |
Cristina Panico, Benedetta Bonora, Antonella Camera, Nino Cristiano Chilelli, Giuliana Da Prato, Giuseppe Favacchio, Valeria Grancini, Veronica Resi, Maurizio Rondinelli, Emanuela Zarra, Basilio Pintaudi. Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review. Cardiovascular Diabetology 2023; 22(1) doi: 10.1186/s12933-023-01855-y
|
| 13 |
Marc Evans, Angharad R. Morgan, Stephen C. Bain, Sarah Davies, Umesh Dashora, Smeeta Sinha, Samuel Seidu, Dipesh C. Patel, Hannah Beba, W. David Strain. Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Therapy 2022; 13(5): 889 doi: 10.1007/s13300-022-01242-y
|
| 14 |
Francesca Oppedisano, Rocco Mollace, Annamaria Tavernese, Micaela Gliozzi, Vincenzo Musolino, Roberta Macrì, Cristina Carresi, Jessica Maiuolo, Maria Serra, Antonio Cardamone, Maurizio Volterrani, Vincenzo Mollace. PUFA Supplementation and Heart Failure: Effects on Fibrosis and Cardiac Remodeling. Nutrients 2021; 13(9): 2965 doi: 10.3390/nu13092965
|
| 15 |
Jean-Sébastien Hulot, Jean-Noël Trochu, Erwan Donal, Michel Galinier, Damien Logeart, Pascal De Groote, Yves Juillière. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options. Expert Opinion on Pharmacotherapy 2021; 22(14): 1847 doi: 10.1080/14656566.2021.1937121
|
| 16 |
Allen Yan Lun Liu, Serena Low, Ester Yeoh, Eng Kuang Lim, Claude Jeffrey Renaud, Selene Tse Yen Teoh, Grace Feng Ling Tan, Chung Cheen Chai, Bo Liu, Tavintharan Subramaniam, Chee Fang Sum, Su Chi Lim. A real-world study on SGLT2 inhibitors and diabetic kidney disease progression. Clinical Kidney Journal 2022; 15(7): 1403 doi: 10.1093/ckj/sfac044
|
| 17 |
Marcelino Cortés, Oscar Lorenzo, Jairo Lumpuy-Castillo, Sacramento Martínez-Albaladejo, Mikel Taibo-Urquía, Ana María Pello, Antonio José Bollas, Miguel Orejas, Miguel Ángel Navas, Ester Macia, María Esther Martínez, Andrea Rueda, Jose Tuñón. Dapagliflozin Improved Cardiac Function and Structure in Diabetic Patients with Preserved Ejection Fraction: Results of a Single Centre, Observational Prospective Study. Journal of Clinical Medicine 2023; 12(20): 6698 doi: 10.3390/jcm12206698
|
| 18 |
Diego Chambergo-Michilot, Astrid Tauma-Arrué, Silvana Loli-Guevara. Effects and safety of SGLT2 inhibitors compared to placebo in patients with heart failure: A systematic review and meta-analysis. IJC Heart & Vasculature 2021; 32: 100690 doi: 10.1016/j.ijcha.2020.100690
|
| 19 |
Xiaodong Hu, Yue Yang, Xiaona Hu, Xiaomeng Jia, Hongzhou Liu, Minjie Wei, Zhaohui Lyu. Effects of sodium‐glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta‐analysis. Diabetes, Obesity and Metabolism 2022; 24(2): 228 doi: 10.1111/dom.14570
|
| 20 |
Bogdan-Sorin Tudurachi, Larisa Anghel, Andreea Tudurachi, Radu Andy Sascău, Răzvan-Liviu Zanfirescu, Cristian Stătescu. Unraveling the Cardiac Matrix: From Diabetes to Heart Failure, Exploring Pathways and Potential Medications. Biomedicines 2024; 12(6): 1314 doi: 10.3390/biomedicines12061314
|